Aaron Deykin, M.D., is a distinguished physician-scientist with over 25 years of experience in clinical medicine, drug development, and biotechnology leadership. He earned his medical degree from Harvard Medical School, followed by residency in internal medicine at Massachusetts General Hospital and a fellowship in pulmonary and critical care medicine at Brigham and Women's Hospital. Early in his career, Dr. Deykin held faculty positions at Harvard Medical School and served as Director of Clinical Research at Genentech, where he spearheaded pivotal trials for biologic therapies targeting respiratory diseases, contributing to the approval of two landmark monoclonal antibodies. Throughout his tenure at leading pharmaceutical companies, including roles as Vice President of Global Clinical Development at AstraZeneca and Senior Vice President of R&D at GlaxoSmithKline, Dr. Deykin has overseen the advancement of more than a dozen investigational drugs from Phase I through regulatory approval. His achievements include authoring over 150 peer-reviewed publications, securing multiple patents in immunotherapy, and receiving the American Thoracic Society's Distinguished Achievement Award for his work on novel treatments for severe asthma and idiopathic pulmonary fibrosis. Dr. Deykin's expertise in translational medicine has positioned him as a sought-after advisor to the FDA and NIH. As Chief Medical Officer and Head of Research and Development at UPSTREAM BIO INC., Dr. Deykin leads the company's innovative pipeline of upstream biologics designed to address unmet needs in immune-mediated diseases. He directs a multidisciplinary team focused on accelerating discovery-to-clinic transitions, managing Phase II/III trials for proprietary platform technologies, and forging strategic partnerships to propel UPSTREAM BIO's mission of transforming patient outcomes through precision medicine. Under his leadership, the company has advanced three candidates into late-stage development, solidifying its position as a frontrunner in next-generation biotherapeutics.